Clinical Trial Update: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

Withdrawal of a Phase 1/2 clinical trial evaluating selinexor in combination regimens for relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Diffuse Large B-cell Lymphoma

Drugs mentioned

• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN